3jzk › Citations

Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.

Allen JG, Bourbeau MP, Wohlhieter GE, Bartberger MD, Michelsen K, Hungate R, Gadwood RC, Gaston RD, Evans B, Mann LW, Matison ME, Schneider S, Huang X, Yu D, Andrews PS, Reichelt A, Long AM, Yakowec P, Yang EY, Lee TA, Oliner JD
J Med Chem 52 7044-53 (2009)
Cited: 73 times
EuropePMC logo PMID: 19856920

Abstract

Tumor protein 53 (p53) is a critical regulator of cell cycle and apoptosis that is frequently disabled in human tumors. In many tumor types, p53 is deleted or mutated, but in others p53 is inactivated by overexpression or amplification of its negative regulator mouse double minute 2 (MDM2). A high-throughput screening effort identified 6,7-bis(4-bromophenyl)-7,12-dihydro-6H-chromeno[4,3-d][1,2,4]triazolo[1,5-a]pyrimidine as a potent inhibitor of the MDM2-p53 protein-protein interaction. This screening hit was found to be chemically unstable and difficult to handle due to poor DMSO solubility. Co-crystallization with the target protein helped to direct further optimization and provided a tractable lead series of novel MDM2-p53 inhibitors. In cellular assays, these compounds were shown to upregulate p53 protein levels and p53 signaling and to cause p53-dependent inhibition of proliferation and apoptosis.

Reviews - 3jzk mentioned but not cited (5)

  1. The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Popowicz GM, Dömling A, Holak TA. Angew Chem Int Ed Engl 50 2680-2688 (2011)
  2. Chemical Variations on the p53 Reactivation Theme. Ribeiro CJ, Rodrigues CM, Moreira R, Santos MM. Pharmaceuticals (Basel) 9 E25 (2016)
  3. Ubiquitination Regulators Discovered by Virtual Screening for the Treatment of Cancer. Song YQ, Wu C, Wu KJ, Han QB, Miao XM, Ma DL, Leung CH. Front Cell Dev Biol 9 665646 (2021)
  4. Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions. Ershov PV, Mezentsev YV, Ivanov AS. Biomolecules 12 106 (2022)
  5. Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies. Moshawih S, Lim AF, Ardianto C, Goh KW, Kifli N, Goh HP, Jarrar Q, Ming LC. Biomolecules 12 878 (2022)

Articles - 3jzk mentioned but not cited (16)



Reviews citing this publication (18)

  1. Drugging the p53 pathway: understanding the route to clinical efficacy. Khoo KH, Verma CS, Lane DP. Nat Rev Drug Discov 13 217-236 (2014)
  2. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Scott DE, Bayly AR, Abell C, Skidmore J. Nat Rev Drug Discov 15 533-550 (2016)
  3. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. Zhao Y, Aguilar A, Bernard D, Wang S. J Med Chem 58 1038-1052 (2015)
  4. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Lu H, Zhou Q, He J, Jiang Z, Peng C, Tong R, Shi J. Signal Transduct Target Ther 5 213 (2020)
  5. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Edelmann MJ, Nicholson B, Kessler BM. Expert Rev Mol Med 13 e35 (2011)
  6. Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. Pal S, Bhattacharjee A, Ali A, Mandal NC, Mandal SC, Pal M. J Inflamm (Lond) 11 23 (2014)
  7. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action. Qin JJ, Nag S, Voruganti S, Wang W, Zhang R. Curr Med Chem 19 5705-5725 (2012)
  8. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy. Wang W, Hu Y. Med Res Rev 32 1159-1196 (2012)
  9. Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives. Fang Y, Liao G, Yu B. Acta Pharm Sin B 10 1253-1278 (2020)
  10. Chromenes: potential new chemotherapeutic agents for cancer. Patil SA, Patil R, Pfeffer LM, Miller DD. Future Med Chem 5 1647-1660 (2013)
  11. Small molecule activators of the p53 response. Ladds MJGW, Laín S. J Mol Cell Biol 11 245-254 (2019)
  12. Resistance acquisition to MDM2 inhibitors. Cinatl J, Speidel D, Hardcastle I, Michaelis M. Biochem Soc Trans 42 752-757 (2014)
  13. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy. Gupta AK, Bharadwaj M, Kumar A, Mehrotra R. Top Curr Chem (Cham) 375 3 (2017)
  14. Targeting protein-protein interaction interfaces in COVID-19 drug discovery. Chang CK, Lin SM, Satange R, Lin SC, Sun SC, Wu HY, Kehn-Hall K, Hou MH. Comput Struct Biotechnol J 19 2246-2255 (2021)
  15. Recent Synthetic Approaches towards Small Molecule Reactivators of p53. Silva JL, Lima CGS, Rangel LP, Ferretti GDS, Pauli FP, Ribeiro RCB, da Silva TB, da Silva FC, Ferreira VF. Biomolecules 10 E635 (2020)
  16. Determination of the Absolute Configurations of Chiral Drugs Using Chiroptical Spectroscopy. Polavarapu PL. Molecules 21 E1056 (2016)
  17. Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer. Kanakaveti V, Anoosha P, Sakthivel R, Rayala SK, Gromiha MM. Curr Top Med Chem 19 457-466 (2019)
  18. Methods for the Discovery and Identification of Small Molecules Targeting Oxidative Stress-Related Protein-Protein Interactions: An Update. Wu X, Zhang Q, Guo Y, Zhang H, Guo X, You Q, Wang L. Antioxidants (Basel) 11 619 (2022)

Articles citing this publication (34)



Quick links